Gyros Protein Technologies

Gyros Protein Technologies AB operates as a specialized provider of solutions for peptide synthesis and bioanalysis. The company was officially formed in March 2016 through the merger of Sweden-based Gyros AB, a specialist in automated nanoliter-scale immunoassays founded in 2000, and Protein Technologies, Inc., an American provider of peptide synthesis instruments founded in 1985. This strategic consolidation combined Gyros's expertise in microfluidics and immunoassays with Protein Technologies' extensive experience in manufacturing instruments for peptide synthesis. The merger was led by Dan Calvo as CEO and Erik Wiberg as CFO. In a significant milestone, Gyros Protein Technologies was acquired by Mesa Laboratories, Inc. (NASDAQ:MLAB) on October 31, 2019, for a cash consideration of $180 million. Following the acquisition, the company now functions as the core of Mesa Labs' Biopharmaceutical Development division.

The firm's business is centered on accelerating the discovery, development, and manufacturing of biotherapeutics for a global client base that includes pharmaceutical and biotechnology companies, as well as contract research (CRO) and manufacturing (CMO) organizations. Its revenue model is based on the sale of instruments and a significant portion of recurring income from aftermarket consumables and services, which constituted approximately 55% of revenue post-acquisition by Mesa Labs. The company's offerings are categorized into two main product lines: advanced peptide synthesizers and automated immunoassay platforms. The peptide synthesizers, including the Prelude X and PurePep Chorus models, provide tools for creating high-purity peptides, even those with complex or long sequences essential for therapeutic applications. The Gyrolab platform, which includes the xPlore and xPand systems, utilizes proprietary microfluidic, CD-based technology for nanoliter-scale immunoassays. This system significantly reduces the consumption of samples and reagents, increases throughput, and delivers high-quality, reproducible data for applications such as pharmacokinetics, immunogenicity, biomarker analysis, and quantifying bioprocess impurities.

The core benefit of the Gyrolab technology is its efficiency and automation, which minimizes manual handling and variability, allowing for faster analysis and decision-making in drug development workflows. For instance, the system can process 96 to 112 data points in about an hour. The company offers a portfolio of ready-to-use kits for various applications, including quantifying viral titers (AAV and p24), detecting host cell protein impurities, and assessing anti-drug antibodies, which streamlines research and development processes for clients in the rapidly growing cell and gene therapy sectors. Keywords: peptide synthesis, bioanalysis, immunoassay platform, biotherapeutics, microfluidics, drug discovery, biopharmaceutical development, Gyrolab, automated immunoassays, nanoliter-scale, bioprocess, protein analytics, pharmacokinetics, immunogenicity, host cell protein analysis, viral titer, AAV, CRO services, CMO support, Mesa Labs, solid phase peptide synthesizers